FDA documents released earlier today indicated a largely positive review for Xiaflex, a hand-disease drug developed by Auxilium Pharmaceuticals (AUXL). The drug is for the treatment of Dupuytren’s contracture and has enjoyed largely successful Phase III results. The stock is up more than 15% this morning and its options have seen more than 30,000 contracts change hands. Most of this volume is centered in the front-month series, which expire this Friday.
Sprint (S) is up more than 10% today on rumors that T-Mobile is considering making a bid for it. This has drawn a lot of options activity. There have been a lot of trades in the September, October, and November call series. More than 90,000 options have traded in Sprint so far today.
Check out these and other names on the OptionsHouse Hotlist.
No related posts.
Tags: auxilium, auxl, call trading, options trading, s, sprint
